(Q44088446)

29 November 2017

title

Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting (English)

1 reference

29 November 2017

1 reference

M Mafauzy

1

1 reference

29 November 2017

publication date

1 October 2002

1 reference

Diabetes Research and Clinical Practice

29 November 2017

published in

1 reference

29 November 2017

volume

58

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

45-53

1 reference

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

Repaglinide versus glyburide: a one-year comparison trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

Rapid-acting insulin secretagogues: a clinical need?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

Pharmacology and clinical experience with repaglinide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2802%2900104-3

7 January 2021

10.1016/S0168-8227(02)00104-3

Identifiers

DOI

1 reference

29 November 2017

1 reference